BioTime, Inc. (NYSE: BTX ) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a definitive Asset Contribution Agreement with Geron Corporation (Nasdaq: GERN ) to acquire the intellectual property, including patents and patent applications, and other assets related to Geron's human embryonic